• COEP kinds GEAR Therapeutics, as a majority-owned subsidiary, to advance GEAR-modified pure killer (NK) cells into first-in-human research for broad vary of cancers and different therapeutic modalities.
WEXFORD, Pa., March 11, 2025 (GLOBE NEWSWIRE) — COEPTIS, Inc. COEP (“the Firm” or “Coeptis”), a pioneering know-how agency on the forefront of revolutionary biotechnology options right this moment introduced it has efficiently licensed unique worldwide improvement and commercialization rights to the GEAR™ (Gene Edited Antibody Resistant) Cell Remedy Platform, representing a first-in-class method to modifying potent cancer-targeting immune cells to optimize the probability of deep remission in sufferers with hematologic malignancies and different cancers. Coeptis had beforehand held restricted co-development rights to GEAR. As a part of this unique GEAR license settlement with VyGen-Bio, Inc., Coeptis has fashioned a brand new majority-owned subsidiary, GEAR Therapeutics, Inc., with the mission to advance GEAR-based cell remedy in direction of human proof-of-concept research to initially consider GEAR-modified pure killer cells (GEAR-NK) for the remedy of a broad vary of cancers and different therapeutic modalities.
How Is GEAR-NK Anticipated to Improve Present Blood Most cancers Remedies?
Gene-Edited Antibody Resistant NK cells (GEAR-NK) are being developed as novel most cancers technique to permit for modified NK cells to be co-administered with focused monoclonal antibodies (“mAbs”), which within the absence of the GEAR-NK would in any other case be neutralized/eradicated by mAb remedy resulting from a typical receptor shared by each malignant cells and NK cells. GEAR-NK represents a mix most cancers remedy with the potential for considerably improved outcomes for sufferers. The GEAR platform additionally holds the potential to switch hematopoietic stems cells (HSCs) together with mAbs to enhance bone marrow transplant outcomes within the remedy of a broad vary of hematological malignancies.
In response to COEP Scientific Advisory Board member, Evren Alici, M.D., Ph.D., “GEAR-based immunotherapy represents a differentiated method to probably optimize and improve present antibody-based most cancers remedy, equivalent to CD38 mAbs for the remedy of a number of myeloma. By leveraging particular websites, we purpose to allow GEAR-modified immune cells, NK cells on this occasion, to be co-administered together with antibodies in a way that largely avoids undesired ‘on course/off tumor results’ on a plethora of mixture or retargeting therapies. The encouraging pre-clinical proof-of-concept information lead us to consider a GEAR-NK technique holds the potential to advantageously eradicate or scale back the chance of NK cell fratricide whereas bettering scientific profit.” Dr. Alici serves as head of the cell & gene remedy group at Sweden’s famend Karolinska Institutet.
Dave Mehalick, CEO of COEPTIS, expressed pleasure, saying, “This expanded possession of the GEAR know-how is a significant achievement for COEPTIS. The market potential of GEAR is in depth and is pushed by therapeutic want. GEAR, built-in into our allogeneic mobile immunotherapy platform, has the potential to supply a useful, cost-effective therapeutic choice out there to all sufferers in want.”
About VyGen-Bio, Inc.
With operations in Florida, USA and Stockholm, Sweden, VyGen-Bio is a majority-owned subsidiary of Vycellix, Inc (www.Vycellix.com). The Firm’s platforms have been found by analysis scientists based mostly on the Cell & Gene Remedy Group at Karolinska Institutet (KI), Sweden. Moreover, VyGen-Bio is a member-partner in “NextGenNK”, the worldwide Competence Middle for the event of next-generation NK cell-based most cancers immunotherapies based mostly at KI and funded by Sweden’s improvements company, Vinnova. KI is globally acknowledged for its Nobel Meeting, which awards the Nobel Prize in Physiology or Medication. Web site: www.VyGen-Bio.com
About COEPTIS, Inc.
COEPTIS, Inc., along with its subsidiaries Coeptis Prescription drugs, Inc., GEAR Therapeutics, Inc., SNAP Biosciences, Inc., and Coeptis Applied sciences (collectively “Coeptis”), is a biopharmaceutical and know-how firm. The biopharmaceutical divisions concentrate on creating revolutionary cell remedy platforms for most cancers, autoimmune, and infectious illnesses. Coeptis goals to advance remedy paradigms and enhance affected person outcomes by means of its cutting-edge analysis and improvement efforts.
The Firm’s therapeutic portfolio is underscored by property licensed from Deverra Therapeutics, which embody an allogeneic mobile immunotherapy platform and DVX201, a clinical-stage, unmodified pure killer cell remedy know-how. COEPTIS can also be creating a common, multi-antigen CAR know-how licensed from the College of Pittsburgh (SNAP-CAR), alongside GEAR cell remedy and companion diagnostic platforms in collaboration with VyGen-Bio and distinguished medical researchers on the Karolinska Institute.
Constructing on its core competencies, COEPTIS has not too long ago established a Know-how Division, which focuses on enhancing operational capabilities by means of superior applied sciences. This division options AI-powered advertising software program and robotic course of automation instruments acquired from NexGenAI Options Group, designed to optimize enterprise processes and enhance total effectivity.
Headquartered in Wexford, PA, COEPTIS is devoted to advancing its mission throughout the regulatory framework set forth by the FDA, guaranteeing that every one actions align with the very best requirements of compliance and affected person care. For extra data on COEPTIS, go to
Cautionary Word Concerning Ahead-Trying Statements
This press launch and statements of our administration made in connection therewith comprise or might comprise “forward-looking statements” (as outlined in Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended). Ahead-looking statements embody statements regarding our plans, aims, targets, methods, future occasions or efficiency, and underlying assumptions, and different statements which are aside from statements of historic details. Once we use phrases equivalent to “might,” “will,” “intend,” “ought to,” “consider,” “anticipate,” “anticipate,” “challenge,” “estimate” or related expressions that don’t relate solely to historic issues, we’re making forward-looking statements. Ahead-looking statements are usually not a assure of future efficiency and contain important dangers and uncertainties which will trigger the precise outcomes to vary materially and maybe considerably from our expectations mentioned within the forward-looking statements. Components which will trigger such variations embody however are usually not restricted to: (1) the lack to take care of the itemizing of the Firm’s securities on the Nasdaq Capital Market; (2) the lack to acknowledge the anticipated advantages of the Deverra licensed property, which can be affected by, amongst different issues, competitors, the power of the Firm to develop and handle progress economically and rent and retain key staff; (3) the dangers that the Firm’s merchandise in improvement or the newly-licensed property fail scientific trials or are usually not permitted by the U.S. Meals and Drug Administration or different relevant regulatory authorities; (4) prices associated to ongoing asset improvement together with the Deverra licensed property and pursuing the contemplated asset improvement paths; (5) modifications in relevant legal guidelines or rules; (6) the chance that the Firm could also be adversely affected by different financial, enterprise, and/or aggressive components; and (7) the impression of the worldwide COVID-19 pandemic on any of the foregoing dangers and different dangers and uncertainties recognized within the Firm’s filings with the Securities and Alternate Fee (the “SEC”). The foregoing listing of things will not be unique. All forward-looking statements are topic to important uncertainties and dangers together with, however not restricted, to these dangers contained or to be contained in experiences and different filings filed by the Firm with the SEC. For these causes, amongst others, buyers are cautioned to not place undue reliance upon any forward-looking statements on this press launch. Extra components are mentioned within the Firm’s filings made or to be made with the SEC, which can be found for overview at www.sec.gov. We undertake no obligation to publicly revise these forward-looking statements to mirror occasions or circumstances that come up after the date hereof except required by relevant legal guidelines, rules, or guidelines.
Contacts
[email protected]
© 2025 Benzinga.com. Benzinga doesn’t present funding recommendation. All rights reserved.
